Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: A post hoc analysis of a Phase 3b/4 randomised safety study
RMD Open 2024;10:e003912 doi: 10.1136/rmdopen-2023-003912
Risk of composite CV endpoints combining all ischaemic CV events and heart failure were similar for individual and combined TOF doses versus TNFi. The totality of CV risk (MACE-8 plus VTE) was higher with TOF 10mg twice daily versus TNFi. Buch et al conducted a post-hoc analysis on the ORAL Surveillance trial to assess risk across extended MACE endpoints in RA patients treated with either TOF 5mg, TOF 10mg, or TNFi.
Risk of MI was higher with TOF versus TNFi and risk difference in other individual CV outcomes was not suggested. Patients with ASCVD history and/or age ≥65 years showed increased risk across all TOF treatment groups compared to TNFi.
Keywords:
